Advertising
Showing 1 to 15 of 154 entries
BUY
Has owned this many years. It's sensitive to the Covid testing environment, like now during Omicron. So, it's has a nice run from this increasing demand. But the market always looks forward, so Abbott doesn't enjoy that testing rise. They report later this month. She is waiting for a slightly lower entry point. Nobody knows what will happen with Covid, but the pandemic has given them a nice cash cushion while medical devices and diagonistics divisions are doing well and will grow, she think around 8-12%. She likes this long term.
biotechnology / pharmaceutical
COMMENT
An advisor could help the caller decide whether to hold or sell some. He doesn't own either The devices made by Abbott show promise for the stock so there is upside. The pharmaceutical side is not of particular interest. These are relatively defensive stocks but market could gravitate to cyclicals.
biotechnology / pharmaceutical
BUY
A Covid play, but he expects America to still be using their Covid testing kits for a long while to come despite medical breakthroughs.
biotechnology / pharmaceutical
BUY
They report Wednesday. They warned of an earnings shortfall. They created a fast Covid test--great news--but then Delta hit those test sales. He's long owned this. He likes their great medical devices.
biotechnology / pharmaceutical
TOP PICK
Diversified. Generics to EMs, medical devices, diagnostics, nutritionals. Covid tests. Outlook cut in June, as demand for rapid tests dropped. Now we're seeing increases in rapid tests. Good growth in med devices and diabetic monitoring. More in the pipeline. Attractive value. Increases dividend every year. She'd buy it here. Yield is 1.53%. (Analysts’ price target is $129.74)
biotechnology / pharmaceutical

Unlock the Weekly Buzzing Stocks

Become a member Or, Sign In
TOP PICK

There is renewed interest in the pharmaceutical sector after decades of being ignored. They are starting to act like value stocks. A good time to start a position in the pharma sector according to Norman Levine. Mentions have increased 22%.

biotechnology / pharmaceutical
BUY

The pharmaceutical sector has not gone anywhere for decades. Now they are starting to act like value stocks. Owns other pharma companies like J&J and Senofi. Now is a good time to put pharma stocks to your porfolio.

biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Jun 24/20, Up 29%) Recently revised guidance by 10-15% of earnings, as they saw a sharp decline in Covid testing. Still growing earnings in double digits. Medical devices and diagnostics are still doing well. Dividend is not high, but increased consistently. She's buying for new clients on this pullback.
biotechnology / pharmaceutical
DON'T BUY

Fine managers and company. They hold the record in raising dividends by 48 straight years. Super stable. They do diagnostics, nutrition, though spun off a business to Abbvie about 8 years ago. They trade in mid-20sx in PE, and grow by a decent 10%. Problem is this high valuation, so he'd look elsewhere in this space, Abbvie, which he owns.

biotechnology / pharmaceutical
TOP PICK
Two profit centres are the diagnostic testing and medical devices businesses, accounting for 75% of their operating profit. He's long liked this. Last week, they announced that their Covid-testing business has fallen off with the reopening, so shares sold off. But he sees long-term growth. It trades below 23x earnings in line with peers and market. ABT is defensive with strong growth. Offers good US exposure to healthcare. (Analysts’ price target is $123.33)
biotechnology / pharmaceutical
DON'T BUY
It is trading at around 34x earnings. It hasn't done much in the last year. It is where it was last year, maybe 10% up. Compared to the rest of the market, it hasn't moved. Big pharma was out of favour a couple years ago. This has now come back into favour. It is fully valued now. Has had a wonderful run. A little expensive.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick Oct 08/20, Up 0.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $109. To remain disciplined, we recommend covering the balance of the holding. Combined with the previous recommendation to cover 50% of the position, this will result in a net investment gain of 9%.
biotechnology / pharmaceutical
BUY

ABT vs. MRK Both are great companies. ABT is the leading supplier of products to the medical industry. Merck has incredible products as a global pharmaceutical company. You could hold either.

biotechnology / pharmaceutical
BUY

ABT vs. JNJ Healthcare is in a more defensive space, moving up during the pandemic. Likes both. JNJ has a fairly nice dividend at 2.5%. 18x forward earnings for 8% growth. Performing decently, but underperforming the S&P. ABT is more in medical devices. Marginally underperforming since last March. 22x earnings with a higher growth rate of 14%. Bit more torque with ABT, and they're also in the Covid detection space. If he had to choose, it would be ABT.

biotechnology / pharmaceutical
TOP PICK
A diversified US healthcare company in diagnostics, branded pharmaceuticals, nutrition and medical devices. It produces a lot of Covid-testing kits, which has boosted their bottom line. They can maintain double-digit earnings growth based on growth in medical devices. For instance, a diagnostic kit for diabetes (don't need to prick finger) is popular. About 40% of products are sold in emerging markets. They increase their dividend annually, for the past 49 years. Pays a 1.5% dividend. This has pulled back, so buy now. (Analysts’ price target is $133.26)
biotechnology / pharmaceutical
Showing 1 to 15 of 154 entries

Abbott Labs(ABT-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 16

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 18

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 18 stock analysts published opinions about ABT-N. 16 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by on . Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

18 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2022-01-26, Abbott Labs (ABT-N) stock closed at a price of $120.07.